Jump Financial LLC Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Jump Financial LLC bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,105 shares of the biotechnology company's stock, valued at approximately $1,666,000.

Other large investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth $30,000. Exome Asset Management LLC raised its holdings in Ascendis Pharma A/S by 119.2% during the 3rd quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after buying an additional 23,849 shares during the period. GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares during the period. Diversified Trust Co lifted its stake in Ascendis Pharma A/S by 7.4% during the fourth quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company's stock valued at $6,200,000 after buying an additional 3,114 shares in the last quarter. Finally, Crossmark Global Holdings Inc. boosted its holdings in shares of Ascendis Pharma A/S by 28.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 10,435 shares of the biotechnology company's stock worth $1,436,000 after buying an additional 2,315 shares during the period.

Analyst Upgrades and Downgrades

ASND has been the subject of a number of research analyst reports. UBS Group started coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price for the company. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Evercore ISI boosted their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Finally, Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Stock Performance

Shares of ASND traded up $1.94 during trading hours on Friday, reaching $162.39. The stock had a trading volume of 279,620 shares, compared to its average volume of 503,372. The stock has a market capitalization of $9.90 billion, a PE ratio of -22.87 and a beta of 0.54. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37. The company's 50-day moving average is $153.64 and its two-hundred day moving average is $138.68.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. Equities analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.